Moderna (NASDAQ:MRNA) Price Target Raised to $151.00

Moderna (NASDAQ:MRNA - Free Report) had its price target boosted by UBS Group from $143.00 to $151.00 in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also commented on MRNA. Needham & Company LLC restated a hold rating on shares of Moderna in a research report on Thursday, May 2nd. Canaccord Genuity Group raised their target price on Moderna from $91.00 to $106.00 and gave the company a hold rating in a report on Friday. William Blair reiterated a market perform rating on shares of Moderna in a research note on Monday, April 1st. Jefferies Financial Group reissued a buy rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Finally, HSBC reaffirmed a reduce rating and set a $86.00 target price (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of Hold and an average price target of $126.89.

Moderna Trading Down 0.9 %

Shares of NASDAQ:MRNA traded down $1.06 during midday trading on Tuesday, reaching $121.07. 2,892,559 shares of the company's stock were exchanged, compared to its average volume of 4,128,369. The stock has a market cap of $46.40 billion, a price-to-earnings ratio of -7.73 and a beta of 1.57. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $142.79. The firm's 50 day simple moving average is $106.10 and its two-hundred day simple moving average is $95.05. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating analysts' consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business had revenue of $167.00 million during the quarter, compared to analysts' expectations of $93.26 million. During the same period last year, the business earned $0.19 earnings per share. The business's revenue for the quarter was down 91.0% on a year-over-year basis. As a group, sell-side analysts forecast that Moderna will post -7.47 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Noubar Afeyan sold 15,000 shares of the company's stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total value of $1,628,100.00. Following the completion of the transaction, the director now owns 2,131,931 shares in the company, valued at approximately $231,399,790.74. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Moderna news, President Stephen Hoge sold 2,388 shares of Moderna stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now owns 1,515,898 shares of the company's stock, valued at $143,358,473.86. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Noubar Afeyan sold 15,000 shares of the business's stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $108.54, for a total value of $1,628,100.00. Following the completion of the sale, the director now owns 2,131,931 shares of the company's stock, valued at approximately $231,399,790.74. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 139,954 shares of company stock valued at $14,822,576. 15.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Moderna

A number of institutional investors have recently modified their holdings of MRNA. Vanguard Group Inc. increased its stake in Moderna by 22.6% in the fourth quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company's stock valued at $3,372,058,000 after purchasing an additional 6,248,623 shares during the period. Wellington Management Group LLP increased its position in Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company's stock valued at $718,584,000 after acquiring an additional 1,614,460 shares during the period. The Manufacturers Life Insurance Company raised its stake in Moderna by 77.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company's stock valued at $400,367,000 after acquiring an additional 1,690,341 shares during the last quarter. Norges Bank acquired a new stake in Moderna during the 4th quarter worth approximately $347,565,000. Finally, Invesco Ltd. grew its stake in shares of Moderna by 19.8% in the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company's stock valued at $322,887,000 after purchasing an additional 517,683 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.